42564
document
The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women . There is evidence to suggest accelerated bone loss following estrogen cessation . The effect of cessation of raloxifene therapy on bone turnover is unknown . Our aim was to determine the effect of cessation of raloxifene treatment on bone turnover and bone mineral density ( BMD ) in postmenopausal , osteopenic women . Women aged 50 to 80 years received raloxifene for 96 weeks and were then randomized to continue raloxifene ( group 1 , n=20 ) or placebo ( group 2 , n=20 ) for a further 96 weeks . A third group ( group 3 , n=14 ) received no treatment . Bone turnover markers and bone density ( BMD ) were measured throughout the study . Raloxifene treatment for 96 weeks resulted in a decrease in bone turnover ( PINP by 31 % ) and an increase in spine BMD ( by 2 % ) but no change in hip BMD for groups 1 and 2 . Continuation of raloxifene ( group 1 ) maintained these changes . Following cessation of raloxifene ( group 2 ) , bone markers returned to baseline levels ( by 120 weeks ) . Hip BMD was decreased by 2 % at 192 weeks compared to baseline . Bone markers in the controls ( group 3 ) remained at the upper limit of the reference range throughout , with decreases in BMD of 2.3 % ( spine ) and 2.8 % ( hip ) . Bone loss following cessation of raloxifene therapy at 96 weeks was greater than in the control group , suggesting accelerated bone loss . The beneficial effect on bone turnover of 96 weeks of raloxifene was lost 6 months after cessation of treatment .
42565
Intervention_Pharmacological
raloxifene
42566
Intervention_Pharmacological
raloxifene
42567
Intervention_Pharmacological
raloxifene
42568
Intervention_Pharmacological
raloxifene
42569
Intervention_Pharmacological
raloxifene
42570
Intervention_Control
or placebo
42571
Intervention_Control
no treatment .
42572
Intervention_Pharmacological
Raloxifene
42573
Intervention_Pharmacological
raloxifene
42574
Intervention_Pharmacological
raloxifene
42575
Intervention_Pharmacological
raloxifene
42576
Outcome_Physical
bone loss
42577
Outcome_Physical
bone turnover
42578
Outcome_Physical
bone mineral density ( BMD )
42579
Outcome_Physical
Bone turnover markers and bone density ( BMD )
42580
Outcome_Physical
decrease in bone turnover
42581
Outcome_Physical
increase in spine BMD
42582
Outcome_Physical
hip BMD
42583
Outcome_Physical
bone markers
42584
Outcome_Physical
Hip BMD
42585
Outcome_Physical
Bone markers
42586
Outcome_Physical
BMD
42587
Outcome_Physical
Bone loss
42588
Outcome_Physical
bone turnover
42589
Participant_Condition
bone turnover in postmenopausal women .
42590
Participant_Condition
accelerated bone loss following estrogen cessation .
42591
Participant_Condition
postmenopausal
42592
Participant_Sex
women
42593
Participant_Sex
Women
42594
Participant_Age
aged 50 to 80 years
42595
Participant_Sample-size
n=20
42596
Participant_Sample-size
n=20
42597
Participant_Sample-size
n=14
42598
Participant_Condition
accelerated bone loss .